Project Oncology
563 FOLLOWERS
Project Oncology presents a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. This series provides cutting-edge updates on cancer biology, diagnosis, and multidisciplinary management, as well as evidence-based recommendations to achieve optimal patient outcomes.
Project Oncology
4h ago
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequen ..read more
Project Oncology
1w ago
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care ..read more
Project Oncology
1w ago
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care ..read more
Project Oncology
1w ago
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care ..read more
Project Oncology
1w ago
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care ..read more
Project Oncology
1w ago
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care ..read more
Project Oncology
3w ago
Guest: Justin Arnall, PharmD, BCOP, CPP
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jerry L. Spivak MD, MACP
After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the overall quality of life of your patient. Tune in with Dr. Charles Turck for insights and experiences from real-life patient cases with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North C ..read more
Project Oncology
3w ago
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Prithviraj Bose, MD
Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center ..read more
Project Oncology
3w ago
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Prithviraj Bose, MD
Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center ..read more
Project Oncology
3w ago
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai ..read more